CBS 2019
CBSMD教育中心
中 文

Transcatheter Aortic Valve Replacement

Abstract

Recommended Article

A Controlled Trial of Rivaroxaban After Transcatheter Aortic-Valve Replacement Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis Minimalist transcatheter aortic valve replacement: The new standard for surgeons and cardiologists using transfemoral access? Determinants and Impact of Heart Failure Readmission Following Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement
|<<... 11 12 13 14 15 16 17 ...>>|

Clinical TrialSeptember 2019

JOURNAL：J Am Coll Cardiol. Article Link

Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis

SJ Baron, EA Magnuson, the PARTNER 3 Investigators. Keywords: low surgical risk; quality of life

ABSTRACT

BACKGROUND - In patients with severe aortic stenosis (AS) at low surgical risk, treatment with transcatheter aortic valve replacement (TAVR) results in lower rates of death, stroke, and re-hospitalization at 1 year compared with surgical aortic valve replacement; however, the effect of treatment strategy on health status is unknown.

OBJECTIVES - This study sought to compare health status outcomes of TAVR vs. surgery in low-risk patients with severe AS.

METHODS - Between 3/2016 and 10/2017, 1000 low-risk AS patients were randomized to transfemoral TAVR using a balloon-expandable valve or surgery in the PARTNER 3 Trial. Health status was assessed at baseline, 1, 6 and 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-36 and EQ-5D. The primary endpoint was change in KCCQ-Overall Summary (KCCQ-OS) score over time. Longitudinal growth curve modeling was used to compare changes in health status between treatment groups over time.

RESULTS - At 1 month, TAVR was associated with better health status than surgery (mean difference in KCCQ-OS 16.0 points; p<0.001). At 6 and 12 months, health status remained better with TAVR, although the effect was reduced (mean difference in KCCQ-OS 2.6 and 1.8 points respectively; p<0.04 for both). The proportion of patients with an excellent outcome (alive with KCCQ-OS ≥ 75 and no significant decline from baseline) was greater with TAVR than surgery at 6 months (90.3% vs. 85.3%; p=0.03) and 12 months (87.3% vs. 82.8%; p=0.07).

CONCLUSIONS - Among low-risk patients with severe AS, TAVR was associated with meaningful early and late health status benefits compared with surgery.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top